98%
921
2 minutes
20
Background: Psoriasis is linked to an increased risk of atrial fibrillation (AF). However, data on the electrophysiological substrate and outcomes of AF ablation in patients with psoriasis are lacking.
Methods: We conducted a retrospective, multicenter study involving 48 patients with psoriasis (median age, 66 years [56-72]; 79% male) and paroxysmal (n=25.52%) or persistent AF (n=23.48%) who underwent ablation at 4 high-volume institutions between 2018 and 2023. Propensity score-matching identified 96 controls without psoriasis undergoing AF ablation at the same institutions. The primary end point was survival free from atrial tachyarrhythmia recurrence after an 8-week blanking period.
Results: Baseline clinical characteristics were well balanced between groups. However, patients with psoriasis had higher CRP (C-reactive protein) than controls (0.85 mg/dL [0.45-1.2] versus 0.3 mg/dL [0.3-0.4], <0.001) and a greater burden of left atrial low-voltage regions at electroanatomical mapping (20% [11%-20%] versus 5% [5%-10%]; =0.013). Over a median follow-up of 20 (13-32) months, atrial tachyarrhythmia recurrence occurred in a higher proportion of patients with psoriasis (40% versus 24%, log-rank =0.023). Patients with psoriasis also had a slightly higher risk of acute coronary syndrome (log-rank =0.045), with similar risks of death (log-rank =0.517) and procedural complications (2% versus 2%, =1.000), whereas no stroke occurred. Multivariable analysis identified early recurrence within blanking period (adjusted hazard ratio [aHR], 5.9, <0.001), preablation CRP levels (aHR, 1.2, =0.016), and psoriasis history (aHR, 2.2, =0.046) as predictors of atrial tachyarrhythmia recurrence. In the group with psoriasis, the optimal CRP cutoff associated with atrial tachyarrhythmia recurrence was found to be 1 mg/dL.
Conclusions: Psoriasis is associated with low-grade systemic inflammation, more severe electroanatomical markers of atrial cardiomyopathy, and worse postablation outcomes. The association between CRP levels and rhythm outcomes suggests that inflammation may drive recurrences among patients with psoriasis undergoing AF ablation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132748 | PMC |
http://dx.doi.org/10.1161/JAHA.124.038882 | DOI Listing |
Dermatol Ther (Heidelb)
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Bologna, Italy.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.
View Article and Find Full Text PDFRheumatol Int
September 2025
Division of Rheumatology and Immunology, Department of PMR, , Sakarya University School of Medicine, Sakarya, Turkey.
To identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within ± 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO).
View Article and Find Full Text PDFJ Med Chem
September 2025
Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Psoriasis is a chronic inflammatory disease that affects the quality of life of patients. The aromatic hydrocarbon receptor (AHR) plays a pivotal role in maintaining the skin barrier integrity. In this study, we conducted a comprehensive analysis of the structure-activity relationship of Tapinarof analogues.
View Article and Find Full Text PDFAustralas J Dermatol
September 2025
Department of Dermatology, Consorcio Hospital General Universitario, Valencia, Spain.
Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation.
View Article and Find Full Text PDFJ Dermatol
September 2025
Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
The long-term impact of biologic therapy on malignancy risk in patients with psoriasis remains unclear. Given the chronic nature of psoriasis and the increasing use of biologics, understanding their long-term safety profile is crucial. This study aimed to compare the incidence of malignancy between patients receiving continuous biologic therapy and those treated with topical monotherapy.
View Article and Find Full Text PDF